Market news

Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.

The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.

REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026.

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.

The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Adicet Bio (NASDAQ:ACET) expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Grow

REDWOOD CITY, Calif., July 21, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.